The role of hyperglycaemia and the hypercoagulable state in the pathogenesis of cardiovascular events in diabetes mellitus: Implications for hypertension management

被引:9
作者
Lim, Hoong Sern [1 ]
MacFadyen, Robert J. [1 ]
Bakris, George [1 ]
Lip, Gregory Y. H. [1 ]
机构
[1] Univ Birmingham Hosp, Dept Med, Haemostasis Thrombosis & Vasc Biol Unit, Birmingham B18 7QH, W Midlands, England
关键词
diabetes; endothelium; glucose; insulin resistance; thrombosis;
D O I
10.2174/138161206776843322
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Population studies have identified diabetes mellitus as a risk factor for cardiac and vascular events, with a common association with hypertension. Observational studies have consistently demonstrated blood glucose as a continuous cardiovascular risk factor. Experimental studies suggest that elevated blood glucose, through a range of biochemical pathways can promote atherogenesis and increase the tendency for thrombosis. The resultant state promotes occlusion of arterial flow and increase cardiovascular event rates. However, an unconvincing temporal relationship (raised blood glucose preceding cardiovascular events) and the limited impact of glucose reduction in patients with diabetes on cardiovascular events do not support blood glucose as a major cause of cardiovascular disease. In this review, we discuss the relationship between hyperglycaemia and a hypercoagulable state in diabetes and the implications of this relationship for the treatment of patients with diabetes, who also commonly have hypertension.
引用
收藏
页码:1567 / 1579
页数:13
相关论文
共 143 条
[1]   The influence of diabetes mellitus on acute and late clinical outcomes following coronary stent implantation [J].
Abizaid, A ;
Kornowski, R ;
Mintz, GS ;
Hong, MK ;
Abizaid, AS ;
Mehran, R ;
Pichard, AD ;
Kent, KM ;
Satler, LF ;
Wu, HS ;
Popma, JJ ;
Leon, MB .
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 1998, 32 (03) :584-589
[2]   Influence of diabetes on 5-year mortality and morbidity in a randomized trial comparing CABG and PTCA in patients with multivessel disease - The bypass angioplasty revascularization investigation (BARI) [J].
Alderman, E ;
Bourassa, M ;
Brooks, MM ;
Califf, R ;
Chaitman, B ;
Detre, K ;
Faxon, DP ;
Feit, F ;
Frye, RL ;
Hardison, RM ;
Holmes, D ;
Holubkov, R ;
Kouchoukos, N ;
Krone, R ;
Rogers, W ;
Rosen, AD ;
Schaff, H ;
Schwartz, L ;
Siewers, AS ;
Sopko, G ;
SuttonTyrrell, K ;
Whitlow, P .
CIRCULATION, 1997, 96 (06) :1761-1769
[3]   Production of plasminogen activator inhibitor 1 by human adipose tissue - Possible link between visceral fat accumulation and vascular disease [J].
Alessi, MC ;
Peiretti, F ;
Morange, P ;
Henry, M ;
Nalbone, G ;
JuhanVague, I .
DIABETES, 1997, 46 (05) :860-867
[4]   NCEP-defined metabolic syndrome, diabetes, and prevalence of coronary heart disease among NHANES III participants age 50 years and older [J].
Alexander, CM ;
Landsman, PB ;
Teutsch, SM ;
Haffner, SM .
DIABETES, 2003, 52 (05) :1210-1214
[5]   TISSUE-TYPE PLASMINOGEN-ACTIVATOR ANTIGEN AND PLASMINOGEN-ACTIVATOR INHIBITOR IN DIABETES-MELLITUS [J].
AUWERX, J ;
BOUILLON, R ;
COLLEN, D ;
GEBOERS, J .
ARTERIOSCLEROSIS, 1988, 8 (01) :68-72
[6]  
Balkau B, 1999, DIABETIC MED, V16, P442
[7]  
BARAZZONI R, 2000, J CLIN ENDOCR METAB, P3121
[8]  
Beckman JS, 1996, AM J PHYSIOL-CELL PH, V271, pC1424
[9]  
Blann AD, 1997, THROMB HAEMOSTASIS, V77, P1077
[10]   Postprandial blood glucose as a risk factor for cardiovascular disease in Type II diabetes: the epidemiological evidence [J].
Bonora, E ;
Muggeo, M .
DIABETOLOGIA, 2001, 44 (12) :2107-2114